Stock News

Web.com Group, Inc. (WEB) Reaches $17.70 After 8.00% Down Move; 6 Bullish Analysts Covering Cymabay Therapeutics, Inc. (CBAY)

The stock of Web.com Group, Inc. (NASDAQ:WEB) is a huge mover today! The stock decreased 18.06% or $3.9 during the last trading session, reaching $17.7. About 936,591 shares traded or 278.39% up from the average. Web.com Group, Inc. (NASDAQ:WEB) has risen 26.30% since February 9, 2017 and is uptrending. It has outperformed by 9.60% the S&P500.The move comes after 6 months negative chart setup for the $862.70M company. It was reported on Feb, 9 by Barchart.com. We have $16.28 PT which if reached, will make NASDAQ:WEB worth $69.02M less.

Among 6 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc had 20 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has “Neutral” rating given on Wednesday, January 4 by H.C. Wainwright. On Wednesday, January 10 the stock rating was maintained by Oppenheimer with “Buy”. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by Cantor Fitzgerald on Wednesday, October 25. On Monday, July 17 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was initiated by Piper Jaffray on Tuesday, July 21 with “Overweight”. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has “Buy” rating given on Monday, January 30 by H.C. Wainwright. Leerink Swann maintained the shares of CBAY in report on Tuesday, November 28 with “Buy” rating. Cantor Fitzgerald initiated the shares of CBAY in report on Tuesday, September 19 with “Buy” rating. H.C. Wainwright downgraded Cymabay Therapeutics, Inc. (NASDAQ:CBAY) on Wednesday, June 1 to “Neutral” rating. The rating was initiated by H.C. Wainwright with “Buy” on Tuesday, September 8. See Cymabay Therapeutics, Inc. (NASDAQ:CBAY) latest ratings:

31/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $15.0 Maintain
25/01/2018 Broker: Roth Capital Rating: Buy New Target: $27.0 Initiate
24/01/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $12 New Target: $18 Maintain
10/01/2018 Broker: Oppenheimer Rating: Buy New Target: $15.0 Maintain
28/11/2017 Broker: Leerink Swann Rating: Buy New Target: $16.0 Maintain
25/10/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0 Maintain
19/09/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0 Initiate
11/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $12.0 Maintain
23/08/2017 Broker: Leerink Swann Rating: Outperform New Target: $12 Initiates Coverage On

The stock decreased 1.42% or $0.1699 during the last trading session, reaching $11.8301. About 644,957 shares traded. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has risen 69.26% since February 9, 2017 and is uptrending. It has outperformed by 52.56% the S&P500.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $655.94 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

Web.com Group, Inc. provides a range of Internet services to small businesses in North America, South America, and the United Kingdom. The company has market cap of $862.70 million. The firm offers a range of Web services and products that enable small businesses to establish, maintain, promote, and optimize their online presence. It has a 36.05 P/E ratio. It provides domain name registration, such as .com and .net domains, as well as a suite of domain name services, including domain name registration, transfer, renewal, expiration protection, and privacy services.

Among 4 analysts covering Web.com Group (NASDAQ:WEB), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Web.com Group had 7 analyst reports since December 30, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Wednesday, December 30 by Suntrust Robinson. The rating was downgraded by Suntrust Robinson to “Hold” on Friday, November 4. The stock has “Sector Perform” rating by RBC Capital Markets on Tuesday, February 16. RBC Capital Markets maintained the stock with “Sector Perform” rating in Friday, May 6 report. The firm has “Buy” rating given on Tuesday, January 19 by Craig Hallum. The firm has “Hold” rating by Cantor Fitzgerald given on Wednesday, October 19. The firm has “Buy” rating given on Friday, February 12 by Suntrust Robinson.

Leave a Reply

Your email address will not be published. Required fields are marked *